Rucaparib (Rubraca▼): withdrawal of third-line treatment indication

2022-09-26T16:19:36+01:00

The third-line treatment indication for rucaparib has been withdrawn following a review of the findings of the ARIEL-4 trial, which showed lower overall survival for rucaparib treatment versus standard chemotherapy in patien…